Crohn Disease
Conditions
Keywords
Crohn, MRI
Brief summary
The investigators plan a prospective study designed to optimize and translate noncontrast, novel Magnetic Resonance Imaging (MRI) techniques for detecting and measuring intestinal inflammation as well as for allowing early prediction of response to medical therapy in small bowel Crohn's Disease (CD).
Detailed description
The investigators plan to evaluate novel MRI techniques to measure: 1) mesenteric/intestinal blood flow using phase-contrast cine MRI, 2) intestinal motility (peristalsis) using dynamic cine MRI, and 3) bowel wall perfusion and molecular water diffusion. Precise objective measurements of diseased bowel blood flow (in ml/min) and bowel motility (in contractions per minute) are not currently used in the clinical care of CD patients, while diffusion-weighted imaging is typically used in a qualitative manner. None of these techniques have been evaluated for predicting eventual response to therapy or correlated with endoscopic mucosal healing in pediatric or adult CD.
Interventions
DEVICEMR Imaging
Novel MR imaging will be performed to provide bowel anatomic and functional data
Sponsors
Children's Hospital Medical Center, Cincinnati
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
11 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy Control Group -Be able to tolerate up to 45 minutes in an MRI scanner Newly Diagnosed Crohns Group * Newly diagnosed, pathology-confirmed diagnosis of small bowel Crohn's disease, * Expected to receive infliximab (Remicade; Janssen Biotech, Inc.) or other anti-Tumor Necrosis Factor (anti-TNF) medical therapy, * Between 11 to 25 years of age and able to assent/consent, * Be available for follow-up MRI at 4-weeks and 6-months after the initiation of treatment, * Be able to tolerate up to 45 minutes in an MRI scanner.
Exclusion criteria
Healthy Control Group * Inability to obtain assent/consent, * Inability to tolerate 45 minutes in an MRI scanner, * Contraindication to MRI (e.g., MRI incompatible implant or support device), * Previous (remote) diagnosis or treatment of inflammatory bowel disease or other intestinal disease, * History of intra-abdominal surgery, including surgery on the intestine, * Pregnancy. Point-of-care urine pregnancy testing will be performed on all female study participants of reproductive potential (pediatric and adult) prior to each research MRI exam. Newly Diagnosed Crohns Group * Inability to obtain assent/consent, * Inability to tolerate 45 minutes in an MRI scanner, * Contraindication to MRI (e.g., MRI incompatible implant or support device), * Previous (remote) diagnosis or treatment of inflammatory bowel disease, * History of intra-abdominal surgery, including surgery on the intestine, * Known bleeding disorder/coagulopathy (contraindication for adult subjects, as this may increase the risk of research colonoscopy), * Pregnancy. Point-of-care urine pregnancy testing will be performed on all female study participants of reproductive potential (pediatric and adult) prior to each research MRI exam.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of therapeutic response in patients with Crohns disease | 30 minutes | Assess novel MRI techniques for ability to predict early response to infliximab therapy in 20 newly diagnosed small bowel CD patients. |
Countries
United States
Outcome results
None listed